Thompson Davis & Co’s Marker Therapeutics MRKR Stock Holding History

Thompson Davis & Co’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$15K	Hold	163	–	–	0.03%	387
2018 Q2	$15K	Buy	+163	New	+$8.31K	0.04%	367

Other funds holding MRKR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

Thompson Davis & Co's MRKR Position: Q3 2018 in Review

Thompson Davis & Co held its Marker Therapeutics (MRKR) position steady in Q3 2018 at 163 shares worth $15K. The position accounts for 0.03% of the portfolio, ranked #387.

Thompson Davis & Co first reported a position in MRKR in Q2 2018 and has held it in 2 quarters since. 31 funds tracked by Wall St. Rank hold MRKR as of Q3 2018.

Thompson Davis & Co held 163 shares of Marker Therapeutics worth $15K as of Q3 2018.
Thompson Davis & Co left its Marker Therapeutics share count unchanged in Q3 2018.
Marker Therapeutics made up 0.03% of Thompson Davis & Co's portfolio in Q3 2018, its #387 holding.
Thompson Davis & Co first reported a position in Marker Therapeutics in Q2 2018 and has held it in 2 quarters since.
31 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.